In a statement, FDA Commissioner Gottlieb explained the growing scientific and public interest in the role of microorganisms in the maintenance of overall health and prevention and treatment of disease. Given the strong interest and rapidly evolving science in the field, FDA convened a workshop co-hosted with the NIH that discussed microbiome-based products and how manipulation of the microbiome may be used to prevent or treat a variety of diseases.
[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
